Hearts & Minds Blog

Delivering on the “Long Game”

Tim Mayleben

President and Chief Executive Officer

I was recently approached by STAT to answer, “How do you balance your long-term goals for your company with the short-term demands of investors?”  My immediate thought seemed obvious: you can’t!  In LDL-cholesterol lowering research and development, in particular, there is no way to balance our long-term timelines with the short-term orientation of many investors – and at Esperion, we don’t try to. Let me explain: clinical development programs for chronic LDL-cholesterol lowering drugs require time; long-term clinical studies of regulatory-submission quality are double-blind with… more

The Lipid Management Team Reflects on the ESC Congress; the World’s Largest Gathering of Cardiovascular Health Experts

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

The Lipid Management Team traveled to Barcelona last month to attend the European Society of Cardiology (ESC) Congress, the world’s largest gathering of cardiovascular health experts. To stay on the cutting-edge of the latest cardiovascular breakthroughs impacting patients with hypercholesterolemia around the world, we attended many late-breaking sessions. We also had the opportunity to discuss these recent breakthroughs with experts in the field. In addition to the overview of the bempedoic acid program presented by Prof. Stephen Nicholls MD, PhD, Professor of Cardiology and Theme… more

Important Bempedoic Acid-Based Franchise Progress Updates

Tim Mayleben

President and Chief Executive Officer

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our bempedoic acid global pivotal Phase 3 program, as well as highly positive Phase 2 results from the combo plus statin study. The Lipid Management Team has been “heads down” making critical advancements for the bempedoic acid franchise both in the clinic and in conversations with regulators that will undoubtedly propel us to a successful second half of the year. First, as you may recall, we… more

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Evolution of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I of our “History of LDL-cholesterol” blog series, I sat down with cardiovascular and lipids specialist, Dr. Antonio M. Gotto, Jr,. to explore the discovery of cholesterol and the development of statins. To continue our conversation focused on cholesterol-lowering treatment options, our next session was centered around therapies that have emerged after statins, and how they have changed the cholesterol treatment landscape. Dr. Gotto’s expertise and years of clinical practice always make for an informative and insightful discussion. Read on for highlights from… more

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval for an LDL-cholesterol lowering indication for our once-daily, oral combination of bempedoic acid 180 mg and ezetimibe 10 mg. The complementary, non-statin combo pill lowers LDL–cholesterol (LDL-C) by almost 50%, while significantly reducing a key marker of inflammation associated with cardiovascular disease known as high-sensitivity C-reactive protein (hsCRP), while potentially lowering the occurrence of muscle-related side effects. As you may recall, this follows our March… more